U.S. markets closed

Kamada Ltd. (KMDA)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
5.61-0.01 (-0.27%)
Al cierre: 04:00PM EDT

Kamada Ltd.

2 Holzman Street
Science Park PO Box 4081
Rehovot 7670402
Israel
972 8 940 6472
https://www.kamada.com

Sector(es)Healthcare
IndustriaDrug Manufacturers - Specialty & Generic
Empleados a tiempo completo378

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Amir LondonChief Executive Officer611kN/D1969
Mr. Chaime OrlevChief Financial Officer387kN/D1970
Mr. Eran NirChief Operating Officer332kN/D1973
Mr. Jon R. KnightVice President of US Commercial Operations307kN/D1966
Mr. Boris GorelikVice President of Business Development & Strategic Programs410kN/D1981
Mr. David TsurCo-Founder & Independent Deputy Chairman of the Board252kN/D1950
Mr. Nir Livneh B.A., L.L.B.VP, General Counsel & Corporate SecretaryN/DN/D1980
Ms. Hanni NehemanVice President of Marketing & SalesN/DN/D1970
Ms. Liron ReshefVice President of Human ResourcesN/DN/D1972
Ms. Shavit BeladevVice President of Kamada PlasmaN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Gestión corporativa

La calificación ISS Governance QuickScore de Kamada Ltd. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.